DB Upgrades CELG to Buy & raises target to $143 with AT LEAST $30 upside to that because of conservative model
DB summary "Survey of 100 dermatologists/rheumatologists suggest Apremilast is a blockbuster. Upgrade CELG to BUY from Neutral & Raise target to $143. We view our model as conservative & see oppies for upside (AT LEAST $30/share)"
See InvestorVillage CELG board for report excerpts (problems posting here again)